Efficacy of micronized purified flavonoid fraction (Daflon®) on improving individual symptoms, signs and quality of life in patients with chronic venous disease: A systematic review and meta-analysis of randomized double-blind placebo-controlled trials

International Angiology

Volumn 37, Issue 2, 2018, Pages 143-154

  Kakkos, Stavros K ^a   Nicolaides, Andrew N ^b,c  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF NICOSIA   (Cyprus)

Author keywords

Flavonoids; Quality of life; Signs and symptoms; Vascular diseases

Indexed keywords

DAFLON; CARDIOVASCULAR AGENT; DIOSMIN;

ANKLE EDEMA; BURNING SENSATION; CHRONIC DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FOOT EDEMA; HUMAN; LEG CRAMP; LEG EDEMA; LEG PAIN; LEG SWELLING; META ANALYSIS; PARESTHESIA; POSTTHROMBOSIS SYNDROME; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESTLESS LEGS SYNDROME; REVIEW; SKIN REDNESS; SYMPTOM; SYSTEMATIC REVIEW; VARICOSIS; VEIN DISEASE; VEIN INSUFFICIENCY; VEIN THROMBOSIS; VENOUS REFLUX; CHI SQUARE DISTRIBUTION; CONVALESCENCE; EDEMA; ODDS RATIO; PATHOPHYSIOLOGY; PSYCHOLOGY; RISK FACTOR; TREATMENT OUTCOME;

CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; DIOSMIN; DOUBLE-BLIND METHOD; EDEMA; HUMANS; ODDS RATIO; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOVERY OF FUNCTION; RISK FACTORS; TREATMENT OUTCOME; VARICOSE VEINS; VENOUS INSUFFICIENCY;

EID: 85044506101     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: 10.23736/S0392-9590.18.03975-5     Document Type: Review

References (53)

1. Nicolaides A, Kakkos S, Eklof B, Perrin M, Nelzen O, Neglen P, et al. Management of chronic venous disorders of the lower limbs - guidelines according to scientific evidence. Int Angiol 2014;33:87-208.
2. Wittens C, Davies AH, Baekgaard N, Broholm R, Cavezzi A, Chastanet S, et al. Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg 2015;49:678-737.
3. Perrin M, Eklof B, Van Rij A, Labropoulos N, Vasquez M, Nicolaides A, et al. Venous symptoms: the SYM Vein Consensus statement developed under the auspices of the European Venous Forum. Int Angiol 2016;35:374-98.
4. Higgins Jpt, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011] ed: The Cochrane Collaboration; 2011.
5. Krief I. Action du Daflon sur la douleur, les crampes et l'oedeme en pathologie veineuse. Etude multicentrique 1200 cas. Lille Med 1980;25:470-2.
6. Laurent R, Gilly R, Frileux C. Clinical evaluation of a venotropic drug in man. Example of Daflon 500 mg. Int Angiol 1988;7:39-43.
7. Elbaz C. The efficacy of daflon 500 mg in 1931 patients suffering from chronic venous insufficiency. Gaz Med 1989;96:30-2.
8. Guillot B, Guilhou JJ, De Champvallins M, Mallet C, Moccatti D, Pointel JP. A long term treatment with a venotropic drug. Results on efficacy and safety of Daflon 500 mg in chronic venous insufficiency. Int Angiol 1989;8:67-71.
9. Henriet JP. The efficacy of daflon 500 mg in 1779 patients with vein insufficiency. Gaz Med 1989;96:85-9.
10. Labrid C. Edema reduction by daflon 500 mg: Pharmacological study. Gaz Med 1989;96:24-9.
11. Galley P, Thiollet M. A double-blind, placebo-controlled trial of a new veno-active flavonoid fraction (S 5682) in the treatment of symptomatic capillary fragility. Int Angiol 1993;12:69-72.
12. Granger C, Laveille C, Vilain C, Jochemsen R. Correlation between haemodynamic parameters of venous tone and clinical symptoms improvement in patients with chronic venous insufficiency. A controlled randomized study Daflon 500 mg 2 tablets per day versus placebo during two months of treatment. Int Angiol 1995;14:343.
13. Galley P, Thiollet M. A double-blind, randomized, placebo controlled trial of Daflon 500 mg in the treatment of symptomatic capillary fragility. Angeiologie 1998;50:101-4.
14. Coleridge-Smith P, Lok C, Ramelet AA. Venous leg ulcer: a metaanalysis of adjunctive therapy with micronized purified flavonoid fraction. Eur J Vasc Endovasc Surg 2005;30:198-208.
15. Pitsch F. Benefit of Daflon 500 mg in chronic venous disease-related symptoms. Phlebolymphology 2005:359-64.
16. Pitsch F. Benefit of daflon 500 mg in chronic venous disease-related edema. Phlebolymphology 2006;13:17-21.
17. Jawien A. Efficacy of Daflon 500 on venous pain: results and perspectives. Phlebology 2008;23:232.
18. Pitsch F. Assessment of treatment efficacy on venous symptoms: The example of Daflon 500 mg. Phlebolymphology 2008;15:137-42.
19. Lenkovic M, Zgombic ZS, Blazic TM, Brajac I, Perisa D. Benefit of Daflon 500 mg in the reduction of chronic venous disease-related symptoms. Phlebolymphology 2012;19:79-83.
20. ∗ (MPFF) improve outcomes of lower extremity varicose veinendovenous treatment? First results from the decision study. Phlebolymphology 2013;20:181-7.
21. Yanushko VA, Bayeshko AA, Sushkov SA, Nebylitsyn YS, Nazaruk AM. Benefits of MPFF on primary chronic venous disease-related symptoms and quality of life: The DELTA study. Phlebolymphology 2014;21:146-51.
22. Biland L, Blattler P, Scheibler P, Studer S, Widmer LK. Zur Therapie sogenannt venoser Beinbeschwerden. (Kontrollierte Doppelblind-Studie zur Untersuchung der therapeutischen Wirksamkeit von Daflon). Vasa 1982;11:53-8.
23. Chassignolle JF, Amiel M, Lanfranchi G, Barbe R. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse fonctionnelle. Journal International de Médicine 1987:32-5.
24. Frileux C, Gilly R. Activité thérapeutique de Daflon 500 mg dans l'insuffisance veineuse chronique des membres inférieurs. Journal International de Médicine 1987:36-9.
25. Tsouderos Y. Are the phlebotonic properties shown in clinical pharmacology predictive of a therapeutic benefit in chronic venous insufficiency? Our experience with Daflon 500 mg. Int Angiol 1989;8:53-9.
26. Planchon B. Insuffisance veineuse et Daflon 500 mg. Arteres et Veines 1990;9:376-80.
27. Thiollet M, Frileux CRG. Evaluation of a new micronized diosmin in the treatment of chronic venous incompetence: a double-blind, placebo controlled trial. J Vasc Surg 1992;15:447.
28. Gilly R, Pillion G, Frileux C. Evaluation of a New Venoactive Micronized Flavonoid Fraction (S 5682) in Symptomatic Disturbances of the Venolymphatic Circulation of the Lower Limb: A Double-Blind, Placebo-Controlled Study. Phlebology 1994;9:67-70.
29. Danielsson G, Jungbeck C, Peterson K, Norgren L. A randomised controlled trial of micronised purified flavonoid fraction vs placebo in patients with chronic venous disease. Eur J Vasc Endovasc Surg 2002;23:73-6.
30. Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R. Venoactive drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology 2014;29:454-60.
31. Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol 2015;34:428-36.
32. Aguilar Peralta GR, Arevalo Gardoqui J, Llamas Macias FJ, Navarro Ceja VH, Mendoza Cisneros SA, Martinez Macias CG. Clinical and capillaroscopic evaluation in the treatment of chronic venous insufficiency with Ruscus aculeatus, hesperidin methylchalcone and ascorbic acid in venous insufficiency treatment of ambulatory patients. Int Angiol 2007;26:378-84.
33. Padberg FT Jr, Maniker AH, Carmel G, Pappas PJ, Silva MB Jr, Hobson RW II. Sensory impairment: a feature of chronic venous insufficiency. J Vasc Surg 1999;30:836-42.
34. Newland MR, Patel AR, Prieto L, Boulton AJ, Pacheco M, Kirsner RS. Neuropathy and gait disturbances in patients with venous disease: a pilot study. Arch Dermatol 2009;145:485-6.
35. Bouskela E, Donyo KA. Effects of oral administration of purified micronized flavonoid fraction on increased microvascular permeability induced by various agents and on ischemia/reperfusion in the hamster cheek pouch. Angiology 1997;48:391-9.
36. Maggioli A. Chronic venous disorders: pharmacological and clinical aspects of micronized purified flavonoid fraction Phlebolymphology 2016;23:82-9.
37. Pascarella L. Essentials of Daflon 500 mg: from early valve protection to long-term benefits in the management of chronic venous disease. Curr Pharm Des 2007;13:431-44.
38. Pascarella L. Daflon and the protection of venous valves. Phlebolymphology 2016;23:20-30.
39. Allegra C, Bartolo M Jr, Carioti B, Cassiani D. An original microhaemorheological approach to the pharmacological effects of Daflon 500 mg in severe chronic venous insufficiency. Int J Microcirc Clin Exp 1995;15 50-4.
40. Bergan JJ, Schmid-Schonbein GW, Takase S. Therapeutic approach to chronic venous insufficiency and its complications: place of Daflon 500 mg. Angiology 2001;52 S43-7.
41. Bouskela E, Cyrino FZ, Lerond L. Effects of oral administration of different doses of purified micronized flavonoid fraction on microvascular reactivity after ischaemia/reperfusion in the hamster cheek pouch. Br J Pharmacol 1997;122:1611-6.
42. Friesenecker B, Tsai AG, Allegra C, Intaglietta M. Oral administration of purified micronized flavonoid fraction suppresses leukocyte adhesion in ischemia-reperfusion injury: in vivo observations in the hamster skin fold. Int J Microcirc Clin Exp 1994;14:50-5.
43. Korthuis RJ, Gute DC. Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc Clin Exp 1997;17:11-7.
44. Shoab SS, Porter J, Scurr JH, Coleridge-Smith PD. Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease-a prospective study. Eur J Vasc Endovasc Surg 1999;17:313-8.
45. Shoab SS, Scurr JH, Coleridge-Smith PD. Plasma VEGF as a marker of therapy in patients with chronic venous disease treated with oral micronised flavonoid fraction - a pilot study. Eur J Vasc Endovasc Surg 1999;18:334-8.
46. Shoab SS, Porter JB, Scurr JH, Coleridge-Smith PD. Effect of oral micronized purified flavonoid fraction treatment on leukocyte adhesion molecule expression in patients with chronic venous disease: a pilot study. J Vasc Surg 2000;31:456-61.
47. Bouskela E, Zely Garcia De Almeida Cyrino F, Das Gracas Coelho De Souza M, de Carvalho JJ. Efficacy of micronized purified flavonoid fraction at the core of inflammation. Int Angiol 2016;35:26.
48. Ibegbuna V, Nicolaides AN, Sowade O, Leon M, Geroulakos G. Venous elasticity after treatment with Daflon 500 mg. Angiology 1997;48:45-9.
49. Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capella D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2005: CD003229.
50. Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, et al. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev 2016: CD003229.
51. Scallon C, Bell-Syer SE, Aziz Z. Flavonoids for treating venous leg ulcers. Cochrane Database Syst Rev 2013: CD006477.
52. Allaert FA. Meta-analysis of the impact of the principal venoactive drugs agents on malleolar venous edema. Int Angiol 2012;31:310-5.
53. Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology 2017;32:3-19.